Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Ryvu Therapeutics SA
RVURyvu Therapeutics S.A., a clinical-stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, synthetic lethality, and immuno-oncology. The company has a research collaboration with Ncage Therapeutics Limited to develop next-generation antibody-drug conjugate (ADC) platform. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland. Address: Leona Henryka Sternbacha 2, Kraków, Poland, 30-394
Analytics
Preço Alvo de Wall Street
323.1 PLNRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave RVU
Análise de Dividendos RVU
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos RVU
Avaliação de ações RVU
Relatório RVU
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |